Renal Manifestations in Patients Diagnosed with Waldenstrom Macroglobulinemia (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO1277; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Given the concern for hyperviscosity syndrome, plasma exchange was instituted while directed treatment with rituximab was begun...Renal dysfunction in these patients remains an important consideration as kidney involvement is present in 3-5% of patients. These cases demonstrate the significant and disparate effects of WM on the renal system along with the importance of a multi-disciplinary approach in the diagnosis and management of this disease."
Clinical • Amyloidosis • B Cell Lymphoma • Complement-mediated Rare Disorders • Hematological Disorders • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Metabolic Disorders • Nephrology • Non-Hodgkin's Lymphoma • Renal Disease • Type 2 Diabetes Mellitus • Waldenstrom Macroglobulinemia • MYD88
|
|
Rachel L. Fine; Ann R. Finke; Taha Ayach; Sayee Sundar Alagusundaramoorthy
|